Key Stories from the past week: China Stimulus Ignites Markets

Key Stories from the past week: China Stimulus Ignites Markets

Macro
Saxo Be Invested
Saxo

Markets have been moving this week after Beijing announced its biggest stimulus since the pandemic in an effort to re-ignite the economic slowdown and subsequent deflation which has plagued China - one of the world largest economies - for a while. Global equities & Precious metals seemed to overall welcome the news with several sectors rallying, especially luxury groups LVMH & Kering trading up on optimism that the stimulus might revive otherwise weakened demand. The Yen has been on a rollercoaster session ahead of Japan's LDP vote and hiking process pressures, and we saw danish pharma giant Novo-Nordisk hit a 6-month low on concerns over competition and pricing. Read more about this week's key stories below:

Hang Seng leaps as China adds to stimulus
After months of economic weakness and speculation the PBOC stepped in and took a more aggressive approach with a number of measures in support of the economy as well as the stock market. This includes among other cutting the 7-day reverse repo rate cut by 20bps, cutting the MLF by 30bps, lower mortgage rates doe existing loads and 500B yuan liquidity support for Chinese stocks. This added on to the risk sentiment that gave way following a 50bps cut by Fed. At Saxo we saw this translated into an increase in number of clients exposed to Hong Kong index by some 10% with 77% of clients being long. 
China’s Bold Stimulus Measures: What It Means for Markets

Novo Nordisk pressured on pricing
Novo Nordisk share price hit a 6-month low and is down almost 20% over the last 10 weeks following the slightly disappointing Q2 results. This week CEO Lars Fruergaard testified in front of the US Senate health committee and that gave rise to more drug-pricing headline noise. Fruergaard promised price cuts, but only if the benefit goes to consumers and not the insurance companies. However, Novo Nordisk continue to hold massive longer term potential and key stock price catalyst in the near term include Rybelsus cardiovascular data and late-stage CagriSema data, which is key to upholding the obesity lead vs. Eli Lilly.

Yen surge after Japan PM election
The yen surged to the upper 142 range against the U.S. dollar after Shigeru Ishiba won Japan's ruling party election, defeating Sanae Takaichi. Ishiba's victory, which positions him to become Japan's next prime minister, led to a brief jump in JPY . Ishiba supports normalizing Japan's monetary policy, causing the yen to strengthen and raising concerns in the stock market due to his stance on financial income taxation.

Next week markets will be monitoring key US jobdata incl. Jobless/continuing claims (Thu), general unemployment & non-farm payrolls (Fri), while also keeping an eye at German inflation data (Mon) & euro area core cpi estimates (Tue). Sports-retail giant Nike that recently named a new CEO is expected to release Q1 25 earnings on Tuesday.


Quarterly Outlook

01 /

  • Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    Quarterly Outlook

    Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    John J. Hardy

    Global Head of Macro Strategy

  • Equity Outlook: The ride just got rougher

    Quarterly Outlook

    Equity Outlook: The ride just got rougher

    Charu Chanana

    Chief Investment Strategist

  • China Outlook: The choice between retaliation or de-escalation

    Quarterly Outlook

    China Outlook: The choice between retaliation or de-escalation

    Charu Chanana

    Chief Investment Strategist

  • Commodity Outlook: A bumpy road ahead calls for diversification

    Quarterly Outlook

    Commodity Outlook: A bumpy road ahead calls for diversification

    Ole Hansen

    Head of Commodity Strategy

  • FX outlook: Tariffs drive USD strength, until...?

    Quarterly Outlook

    FX outlook: Tariffs drive USD strength, until...?

    John J. Hardy

    Global Head of Macro Strategy

  • Fixed Income Outlook: Bonds Hit Reset. A New Equilibrium Emerges

    Quarterly Outlook

    Fixed Income Outlook: Bonds Hit Reset. A New Equilibrium Emerges

    Althea Spinozzi

    Head of Fixed Income Strategy

  • Equity Outlook: Will lower rates lift all boats in equities?

    Quarterly Outlook

    Equity Outlook: Will lower rates lift all boats in equities?

    Peter Garnry

    Chief Investment Strategist

    After a period of historically high equity index concentration driven by the 'Magnificent Seven' sto...
  • Commodity Outlook: Gold and silver continue to shine bright

    Quarterly Outlook

    Commodity Outlook: Gold and silver continue to shine bright

    Ole Hansen

    Head of Commodity Strategy

  • Macro Outlook: The US rate cut cycle has begun

    Quarterly Outlook

    Macro Outlook: The US rate cut cycle has begun

    Peter Garnry

    Chief Investment Strategist

    The Fed started the US rate cut cycle in Q3 and in this macro outlook we will explore how the rate c...
  • FX Outlook: USD in limbo amid political and policy jitters

    Quarterly Outlook

    FX Outlook: USD in limbo amid political and policy jitters

    Charu Chanana

    Chief Investment Strategist

    As we enter the final quarter of 2024, currency markets are set for heightened turbulence due to US ...

Content disclaimer

None of the information provided on this website constitutes an offer, solicitation, or endorsement to buy or sell any financial instrument, nor is it financial, investment, or trading advice. Saxo Bank A/S and its entities within the Saxo Bank Group provide execution-only services, with all trades and investments based on self-directed decisions. Analysis, research, and educational content is for informational purposes only and should not be considered advice nor a recommendation.

Saxo’s content may reflect the personal views of the author, which are subject to change without notice. Mentions of specific financial products are for illustrative purposes only and may serve to clarify financial literacy topics. Content classified as investment research is marketing material and does not meet legal requirements for independent research.

Before making any investment decisions, you should assess your own financial situation, needs, and objectives, and consider seeking independent professional advice. Saxo does not guarantee the accuracy or completeness of any information provided and assumes no liability for any errors, omissions, losses, or damages resulting from the use of this information.

Please refer to our full disclaimer and notification on non-independent investment research for more details.
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/legal/disclaimer/saxo-disclaimer)

Saxo Bank A/S (Headquarters)
Philip Heymans Alle 15
2900
Hellerup
Denmark

Contact Saxo

Select region

International
International

All trading and investing comes with risk, including but not limited to the potential to lose your entire invested amount.

Information on our international website (as selected from the globe drop-down) can be accessed worldwide and relates to Saxo Bank A/S as the parent company of the Saxo Bank Group. Any mention of the Saxo Bank Group refers to the overall organisation, including subsidiaries and branches under Saxo Bank A/S. Client agreements are made with the relevant Saxo entity based on your country of residence and are governed by the applicable laws of that entity's jurisdiction.

Apple and the Apple logo are trademarks of Apple Inc., registered in the US and other countries. App Store is a service mark of Apple Inc. Google Play and the Google Play logo are trademarks of Google LLC.